Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Antipsychotics: to combine or not to combine? (CROSBI ID 213928)

Prilog u časopisu | pregledni rad (stručni)

Šagud, Marina ; Vuksan-Ćusa, Bjanka ; Živković, Maja ; Vlatković, Suzana ; Kramarić, Milivoj ; Bradaš, Zoran ; Mihaljević-Peleš, Alma Antipsychotics: to combine or not to combine? // Psychiatria Danubina, 25 (2013), 3; 306-310

Podaci o odgovornosti

Šagud, Marina ; Vuksan-Ćusa, Bjanka ; Živković, Maja ; Vlatković, Suzana ; Kramarić, Milivoj ; Bradaš, Zoran ; Mihaljević-Peleš, Alma

engleski

Antipsychotics: to combine or not to combine?

Antipsychotic monotherapy is strongly recommended in the treatment of schizophrenia. However, antipsychotic polypharmacy (APP) is common in clinical practice and appears to be related to illness severity and duration, treatment-refractoriness, hospitalization status, duration of hospitalization, geographic region and age. Given the high number of different antipsychotic combinations reported in the literature and prescribed in clinical practice, there are perhaps more differences than similarities between such combinations. While the majority of combinations increase side-effect burden, limited evidence suggests benefits of certain combinations. Until more data are available, APP should be reserved for difficult-to treat patients, with careful consideration of pharmacodynamics properties and doses of each drug, as well as close monitoring.

antypschotics ; combine

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

25 (3)

2013.

306-310

objavljeno

0353-5053

1849-0867

Povezanost rada

Kliničke medicinske znanosti

Indeksiranost